Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287007032> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4287007032 endingPage "84" @default.
- W4287007032 startingPage "79" @default.
- W4287007032 abstract "Treatment of Chronic myeloid leukemia (CML) typically entails a long-term course of tyrosine kinase inhibitors (TKI) therapy. This review provides a summary on the cardiotoxic effects of TKIs. Five small molecular TKIs were evaluated in our review. The cardiotoxic effects of TKIs can range from superficial edema to potentially fatal conditions such as congestive heart failure (HF) and acute coronary syndrome (ACS). With the constant introduction of newer generations of TKIs, it has been demonstrated that different TKIs have distinct cardiovascular safety profiles. Amongst which, the first-generation TKI - imatinib appears to have the safest profile, mainly causing edema along with nausea, rash and muscle cramps. Other TKIs, like the second-generation dasatinib, bosutinib,and nilotinib, have shown an increased incidence of pleural effusion and QT prolongation. Ponatinib, a third generation TKI, has shown a relatively high incidence of serious adverse effects including thrombotic vascular occlusion and heart failure, particularly in patients with a prior history of cardiovascular impairment. Therefore, it is advisable that at-risk patients taking TKIs be screened with an Electrocardiogram (ECG) and have a careful cardiovascular risk assessment before starting TKI therapy to avoid potential cardiotoxic effects such as arrhythmias, acute coronary syndrome (ACS), congestive heart failure, and pleural effusion. Keywords: tyrosine kinase inhibitor, TKI, chronic myelogenous leukemia, CML, cardiotoxicity, side effects, imatinib, dasatinib, bosutinib, nilotinib, ponatinib." @default.
- W4287007032 created "2022-07-25" @default.
- W4287007032 creator A5000584189 @default.
- W4287007032 creator A5006313386 @default.
- W4287007032 creator A5006372661 @default.
- W4287007032 creator A5006659534 @default.
- W4287007032 creator A5069678138 @default.
- W4287007032 creator A5077229825 @default.
- W4287007032 date "2021-09-01" @default.
- W4287007032 modified "2023-10-17" @default.
- W4287007032 title "Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia." @default.
- W4287007032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35152199" @default.
- W4287007032 hasPublicationYear "2021" @default.
- W4287007032 type Work @default.
- W4287007032 citedByCount "0" @default.
- W4287007032 crossrefType "journal-article" @default.
- W4287007032 hasAuthorship W4287007032A5000584189 @default.
- W4287007032 hasAuthorship W4287007032A5006313386 @default.
- W4287007032 hasAuthorship W4287007032A5006372661 @default.
- W4287007032 hasAuthorship W4287007032A5006659534 @default.
- W4287007032 hasAuthorship W4287007032A5069678138 @default.
- W4287007032 hasAuthorship W4287007032A5077229825 @default.
- W4287007032 hasConcept C121608353 @default.
- W4287007032 hasConcept C126322002 @default.
- W4287007032 hasConcept C164705383 @default.
- W4287007032 hasConcept C2776694085 @default.
- W4287007032 hasConcept C2777413986 @default.
- W4287007032 hasConcept C2777583451 @default.
- W4287007032 hasConcept C2778198053 @default.
- W4287007032 hasConcept C2778208673 @default.
- W4287007032 hasConcept C2778233292 @default.
- W4287007032 hasConcept C2778729363 @default.
- W4287007032 hasConcept C2778820342 @default.
- W4287007032 hasConcept C2779490328 @default.
- W4287007032 hasConcept C2779536868 @default.
- W4287007032 hasConcept C2780381907 @default.
- W4287007032 hasConcept C2781175549 @default.
- W4287007032 hasConcept C71924100 @default.
- W4287007032 hasConceptScore W4287007032C121608353 @default.
- W4287007032 hasConceptScore W4287007032C126322002 @default.
- W4287007032 hasConceptScore W4287007032C164705383 @default.
- W4287007032 hasConceptScore W4287007032C2776694085 @default.
- W4287007032 hasConceptScore W4287007032C2777413986 @default.
- W4287007032 hasConceptScore W4287007032C2777583451 @default.
- W4287007032 hasConceptScore W4287007032C2778198053 @default.
- W4287007032 hasConceptScore W4287007032C2778208673 @default.
- W4287007032 hasConceptScore W4287007032C2778233292 @default.
- W4287007032 hasConceptScore W4287007032C2778729363 @default.
- W4287007032 hasConceptScore W4287007032C2778820342 @default.
- W4287007032 hasConceptScore W4287007032C2779490328 @default.
- W4287007032 hasConceptScore W4287007032C2779536868 @default.
- W4287007032 hasConceptScore W4287007032C2780381907 @default.
- W4287007032 hasConceptScore W4287007032C2781175549 @default.
- W4287007032 hasConceptScore W4287007032C71924100 @default.
- W4287007032 hasIssue "37" @default.
- W4287007032 hasLocation W42870070321 @default.
- W4287007032 hasOpenAccess W4287007032 @default.
- W4287007032 hasPrimaryLocation W42870070321 @default.
- W4287007032 hasRelatedWork W11313001 @default.
- W4287007032 hasRelatedWork W13021636 @default.
- W4287007032 hasRelatedWork W15071589 @default.
- W4287007032 hasRelatedWork W16114088 @default.
- W4287007032 hasRelatedWork W16589460 @default.
- W4287007032 hasRelatedWork W17970610 @default.
- W4287007032 hasRelatedWork W18760892 @default.
- W4287007032 hasRelatedWork W2011212 @default.
- W4287007032 hasRelatedWork W2445216 @default.
- W4287007032 hasRelatedWork W6111848 @default.
- W4287007032 hasVolume "1" @default.
- W4287007032 isParatext "false" @default.
- W4287007032 isRetracted "false" @default.
- W4287007032 workType "article" @default.